Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01484041|
Recruitment Status : Terminated (Decision by company to cease development of dovitinib)
First Posted : December 2, 2011
Results First Posted : September 20, 2016
Last Update Posted : February 9, 2018
This study is for women with confirmed hormone receptor positive HER-2 negative advanced breast cancer with evidence of disease resistance to an aromatase inhibitor.
The purpose of this study is to determine how well these medications work together and/or if they have any side effects in patients with hormone-receptor positive metastatic breast cancer who have demonstrated progression of disease after first line hormonal therapy.
This research is being done to determine if taking an already approved medicine (aromatase inhibitor) in combination with a new medication (dovitinib) results in better outcomes for patients with this disease.
Both dovitinib and an aromatase inhibitor are pills that will be taken at home.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Drug: Dovitinib Drug: Aromatase Inhibitors||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/II Trial of TKI258 (Dovitinib) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer|
|Study Start Date :||April 2012|
|Actual Primary Completion Date :||December 2015|
|Actual Study Completion Date :||December 2017|
Experimental: Dovitinib plus aromatase inhibitors
Dovitinib with aromatase inhibitor
Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest
Other Name: TKI258
Drug: Aromatase Inhibitors
Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily
- Clinical Benefit Rate [ Time Frame: 24 weeks ]Complete response, partial response, or stable disease at 24 weeks from trial entry as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression
- Recommended Phase 2 Dose [ Time Frame: 4 weeks ]The dose of dovitinib at which 1 or less subjects experience a dose limiting toxicity when administered every day for 5 days followed by 2 days off schedule in combination with an aromatase inhibitor
- Number of Participants With Adverse Events [ Time Frame: 24 weeks ]Number of participants experiencing adverse events
- Pharmacodynamic Effects [ Time Frame: 24 weeks ]Expression of pFGFR, pFRS2, pERK in tumor tissue and VEGF, bFGF, PLGF, sVEGFR1/2 and FGF23 levels in plasma
- Progression-free Survival [ Time Frame: 24 weeks ]Length of time from study entry until progressive disease
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01484041
|United States, District of Columbia|
|Georgetown Lombardi Comprehensive Cancer Center|
|Washington, District of Columbia, United States, 20007|
|Principal Investigator:||Claudine Isaacs, MD||Georgetown University|